Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

73.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 73.86
Bid (Size) 66.10 (1)
Ask (Size) 79.41 (1)
Prev. Close 73.86
Today's Range 73.86 - 73.86
52wk Range 61.91 - 84.86
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Most Oversold Stocks To Buy In August 2022
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga

Performance

YTD
-0.15%
-0.15%
1 Month
-6.34%
-6.34%
3 Month
+0.64%
+0.64%
6 Month
+8.89%
+8.89%
1 Year
-2.38%
-2.38%

More News

Read More
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
Via Investor's Business Daily
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance
Via Benzinga
Recap: Incyte Q2 Earnings
Via Benzinga
Expert Ratings for Incyte
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
Via Benzinga
New Indication Approval For Incyte "To Usher New Growth Avenue"
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Via Benzinga
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
From Incyte
Via Business Wire
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Via Benzinga
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Twitter And 3 Other Stocks Insiders Are Selling
Via Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Via Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Via Benzinga
7 Defensive Stocks to Buy for a Bear Market
Via InvestorPlace
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
Via Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Via Benzinga
Insights On Incyte Corporation
Via Talk Markets
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.